Lynn B Wahle, in Amherst, NH - Marriage & Family Therapist

Lynn B Wahle, is a Marriage & Family Therapist based in Amherst, New Hampshire. Lynn B Wahle is licensed to practice in * (Not Available) (license number ) and her current practice location is 109 Ponemah Rd Ste 8, Amherst, New Hampshire. She can be reached at her office (for appointments etc.) via phone at (603) 801-2791.

NPI number for Lynn B Wahle is 1639327778 and her current mailing address is 73 Tater St, Mont Vernon, New Hampshire. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1639327778.

Contact Information

	Lynn B Wahle,
	109 Ponemah Rd Ste 8, Amherst, NH 03031-2834
	(603) 801-2791
	Not Available

Healthcare Provider's Profile

Full Name	Lynn B Wahle
Gender	Female
Speciality	Marriage & Family Therapist
Location	109 Ponemah Rd Ste 8, Amherst, New Hampshire
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1639327778
Provider Enumeration Date: 09/03/2008
Last Update Date: 08/16/2019

Medical Identifiers

Medical identifiers for Lynn B Wahle such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1639327778	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
106H00000X	Marriage & Family Therapist	(* (Not Available))	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Lynn B Wahle is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Lynn B Wahle, 73 Tater St, Mont Vernon, NH 03057-1308 Ph: (603) 673-4273	Lynn B Wahle, 109 Ponemah Rd Ste 8, Amherst, NH 03031-2834 Ph: (603) 801-2791

News Archive

FDA approves Remodulin for the treatment of pulmonary arterial hypertension

United Therapeutics Corporation announced today that the U.S. Food and Drug Administration (FDA) has issued an approval letter for the intravenous use of Remodulin based on data establishing its bioequivalence with the previously approved subcutaneous administration of Remodulin.

Key mechanism that makes brain cells become tumorous identified

Researchers from the Peninsula Medical School in Plymouth (UK), the Memorial Sloan-Kettering Cancer Center in New York, Cornell University in New York, Weil Medical College in New York and the Center for Neural Tumour Research in Los Angeles, have for the first time identified a key mechanism that makes certain cells become tumorous in the brain. The resulting tumours occur most often spontaneously but can also occur in numbers as part of the inherited disease Neurofibromatosis type 2.

Stem cells do not participate directly in cartilage regeneration but serve to ‘animate' the process

Stem cell therapy has great potential for curing cartilage damage. However, it has remained unclear whether stem cells are responsible for regeneration or whether they trigger the process.

Binge-drinking from adolescence could have long-term effects on the cardiovascular system

Moderate drinking has been linked to a lower risk of coronary heart disease in several studies. However, the relationship between alcohol and heart disease remains controversial and is challenging to assess.

UCLA scientists developed experimental treatment that eradicates acute type of leukemia in mice

A diverse team of scientists from UCLA's Jonsson Comprehensive Cancer Center have developed an experimental treatment that eradicates an acute type of leukemia in mice without any detectable toxic side effects. The drug works by blocking two important metabolic pathways that the leukemia cells need to grow and spread.

Lynn B Wahle, - Couples Therapy in Amherst, NH